GSK3B and myotonic dystrophy type 1: Clinical trials for DM1 include Tideglusib targeting GSK3β pathway (phase III), Metformin for the splicing defect (phase III), Mexiletine for myotonia (phase III), and antisense oligonucleotides like AOC 1001 (phase III), and NTC0231 targeting repeat secondary structures to displace sequestered proteins (IND enabling phase) (Heatwole et al, 2021; Horrigan et al, 2020; Pascual-Gilabert et al, 2023).